Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.57 |
| ▸ | CNR1 | P21554 | 15/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802246 | 0.93 | CNR2 (0.50) | CNR2CNR1TRPV1 | |
| SCHEMBL10724501 | 0.92 | CNR2 (0.58) | CNR2CNR1TRPV1 | |
| SCHEMBL23601974 | 0.92 | CNR2 (0.55) | CNR2CNR1TRPV1 | |
| SCHEMBL10653170 | 0.90 | CNR1 (0.61) | CNR2CNR1 | |
| SCHEMBL10914094 | 0.89 | CNR2 (0.53) | CNR2CNR1TRPV1 | |
| SCHEMBL23461341 | 0.88 | CNR2 (0.48) | CNR2CNR1TRPV1 | |
| SCHEMBL23461339 | 0.88 | CNR2 (0.48) | CNR2CNR1TRPV1 | |
| SCHEMBL17129735 | 0.85 | ALDH1A1 (0.46) | CNR2CNR1TRPV1 | |
| SCHEMBL23461342 | 0.84 | CNR2 (0.52) | CNR2CNR1TRPV1 | |
| SCHEMBL1171569 | 0.83 | CNR2 (0.51) | CNR2CNR1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4087410-A | 5-(Tertiary alkyl) resorcinol preparation and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | SUTTER BAY HOSPITALS (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250002435-A1 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-01-02 | — | — | US | disclosed |
| EP-4412974-A1 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | ORGANIX INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2023058033-A1 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022133058-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | SUTTER BAY HOSPITALS (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022061461-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2022-03-31 | — | — | WO | disclosed |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20190315669-A1 | PROCESS FOR THE PREPARATION OF HU-910 AND CRYSTALLINE STRUCTURE THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-10-17 | — | — | US | disclosed |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1567513-A2 | HIGH ENANTIOMERIC PURITY DEXANABINOL FOR PHARMACEUTICAL COPOSITIONS | PHARMOS CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050011-A2 | HIGH ENANTIOMERIC PURITY DEXANABINOL FOR PHARMACEUTICAL COPOSITIONS | PHARMOS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-4707559-A | 3-(6-ALKOXY-4-ALKYL-2-HYDROXYPHENYL)CYCLOHEXANOL DERIVATIVES | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1987-11-17 | — | — | US | disclosed |
| US-4131656-A | Intermediates for 5-(tertiary alkyl) resorcinol preparation | ELI LILLY AND COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4087410-A | 5-(Tertiary alkyl) resorcinol preparation and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002435-A1 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | CYP4F2, CYP4F8, CYP4F3 | CNR2 732/4885CNR1 977/4885TRPV1 2590/4885 |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR2 3/4885CNR1 1/4885TRPV1 627/4885 |
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | CARM1, MALT1, RCOR1 | CNR2 397/4885CNR1 115/4885TRPV1 1827/4885 |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | CNR2, CNR1, FAAH | CNR2 1/4885CNR1 2/4885TRPV1 7/4885 |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | CNR2 1/4885CNR1 2/4885TRPV1 143/4885 |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | VHL, NQO1, HRAS | CNR2 3315/4885CNR1 3278/4885TRPV1 3290/4885 |
| US-20190315669-A1 | PROCESS FOR THE PREPARATION OF HU-910 AND CRYSTALLINE STRUCTURE THEREOF | HUWE1, SNRNP200, UACA | CNR2 3253/4885CNR1 2723/4885TRPV1 4771/4885 |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | CNR2 1/4885CNR1 2/4885TRPV1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.